Anti‐PD‐L1/TGF‐βR fusion protein (SHR‐1701) overcomes disrupted lymphocyte recovery‐induced resistance to PD‐1/PD‐L1 inhibitors in lung cancer
Cancer Communications2022Vol. 42(1), pp. 17–36
Citations Over TimeTop 10% of 2022 papers
Bo Cheng, Kaikai Ding, Pengxiang Chen, Jianxiong Ji, Tao Luo, Xiaofan Guo, Wei Qiu, Chunhong Ma, Xue Meng, Jian Wang, Jinming Yu, Yuan Liu
Abstract
Lung cancer patients with poor lymphocyte recovery and suffering from persistent lymphopenia after previous chemotherapy are resistant to anti-PD-1/PD-L1 antibodies but might be sensitive to second-generation agents such as SHR-1701.
Related Papers
- → Electrochemical biosensors for the detection of lung cancer biomarkers: A review(2019)353 cited
- → Molecular Epidemiology of Female Lung Cancer(2011)10 cited
- → Chemoprevention of lung cancer(2001)7 cited
- → [Gender-associated differences of lung cancer and mechanism].(2011)3 cited
- The Expression and Clinical Significance of Adrenomedulin in Patients with Lung Cancer(2006)